Unity Biotechnology Inc

NASDAQ:UBX  
4.20
-0.06 (-1.41%)
Debt Financing / Related, Layoffs, Restructuring / Reorganization

Unity Biotechnology- Initiated Restructuring To Align Resources On Cellular Senescence Programs In Ophthalmology, Neurology

Published: 09/15/2020 13:12 GMT
Unity Biotechnology Inc (UBX) - Unity Biotechnology Inc - Initiated Restructuring to Align Resources on Cellular Senescence Programs in Ophthalmology, Neurology.
Unity Biotechnology Inc - Restructuring to Extend Cash Runway Through Mid-2022 and Key Milestones.
Unity Biotechnology Inc - Will Advance Ubx1325 to Phase 1 Clinical Development in Patients With Diabetic Macular Edema.
Unity Biotechnology Inc - Will Reduce Its Workforce by Approximately 30%.
Unity Biotechnology - Cash, Cash Equivalents Projected to Fund Unity Through Key Clinical Data Readouts for Ubx1325, Ind-enabling Studies for Ubx1967.